Biodexa Pharmaceuticals Plc (BDRX) has released an update.
Biodexa Pharmaceuticals PLC, a NASDAQ-listed biotech firm specializing in innovative cancer and diabetes treatments, reported its 2023 results, highlighting advances in their primary programs for brain cancers and type 1 diabetes. The company has made strides with its drug tolimidone for diabetes and MTX110 for rare brain cancers, leveraging proprietary drug delivery technologies. Following a strategic shift to focus on therapeutics, Biodexa is advancing clinical trials and expanding its development pipeline while maintaining a commitment to a safe and supportive work environment for its staff.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
